Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model.

Field CS, Hunn MK, Ferguson PM, Ruedl C, Ancelet LR, Hermans IF.

Oncoimmunology. 2017 Sep 27;7(1):e1376154. doi: 10.1080/2162402X.2017.1376154. eCollection 2017.

PMID:
29296535
2.

Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function.

Brooks CR, Van Dalen CJ, Harding E, Hermans IF, Douwes J.

BMC Pulm Med. 2017 Dec 4;17(1):169. doi: 10.1186/s12890-017-0511-6.

3.

A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.

Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, Mester B, Dzhelali M, Caygill G, Jones J, Hayman CM, Hinder VA, Macapagal J, McCusker M, Weinkove R, Painter GF, Brimble MA, Findlay MP, Dunbar PR, Hermans IF.

Cancer Immunol Immunother. 2018 Feb;67(2):285-298. doi: 10.1007/s00262-017-2085-9. Epub 2017 Nov 1.

PMID:
29094183
4.

Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins.

Speir M, Authier-Hall A, Brooks CR, Farrand KJ, Compton BJ, Anderson RJ, Heiser A, Osmond TL, Tang CW, Berzofsky JA, Terabe M, Painter GF, Hermans IF, Weinkove R.

Sci Rep. 2017 Oct 27;7(1):14273. doi: 10.1038/s41598-017-14690-5.

5.

Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.

Anderson RJ, Li J, Kedzierski L, Compton BJ, Hayman CM, Osmond TL, Tang CW, Farrand KJ, Koay HF, Almeida CFDSSE, Holz LR, Williams GM, Brimble MA, Wang Z, Koutsakos M, Kedzierska K, Godfrey DI, Hermans IF, Turner SJ, Painter GF.

ACS Chem Biol. 2017 Nov 17;12(11):2898-2905. doi: 10.1021/acschembio.7b00845. Epub 2017 Oct 27.

PMID:
29043774
6.

Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells.

Salio M, Gasser O, Gonzalez-Lopez C, Martens A, Veerapen N, Gileadi U, Verter JG, Napolitani G, Anderson R, Painter G, Besra GS, Hermans IF, Cerundolo V.

J Immunol. 2017 Oct 15;199(8):2631-2638. doi: 10.4049/jimmunol.1700615. Epub 2017 Sep 6.

7.

Sputum basophils are increased in eosinophilic asthma compared with non-eosinophilic asthma phenotypes.

Brooks CR, van Dalen CJ, Hermans IF, Gibson PG, Simpson JL, Douwes J.

Allergy. 2017 Oct;72(10):1583-1586. doi: 10.1111/all.13185. Epub 2017 Jun 1.

PMID:
28426171
8.

Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Speir M, Hermans IF, Weinkove R.

Drugs. 2017 Jan;77(1):1-15. doi: 10.1007/s40265-016-0675-z. Review.

PMID:
28005229
9.

Determining mean fractional anisotropy using DDCOSY: preliminary results in biological tissues.

Zong F, Ancelet LR, Hermans IF, Galvosas P.

Magn Reson Chem. 2017 May;55(5):498-507. doi: 10.1002/mrc.4492. Epub 2016 Aug 21.

PMID:
27487091
10.

Poly Ethoxy Ethyl Glycinamide (PEE-G) Dendrimers: Dendrimers Specifically Designed for Pharmaceutical Applications.

Toms S, Carnachan SM, Hermans IF, Johnson KD, Khan AA, O'Hagan SE, Tang CW, Rendle PM.

ChemMedChem. 2016 Aug 5;11(15):1583-6. doi: 10.1002/cmdc.201600270. Epub 2016 Jul 8.

PMID:
27390296
11.

Whole tumor cell vaccines for glioma immunotherapy.

Field CS, Hermans IF, Hunn MK.

Immunotherapy. 2016;8(4):387-9. doi: 10.2217/imt-2015-0022. No abstract available.

12.

Synthesis and Activity of 6″-Deoxy-6″-thio-α-GalCer and Peptide Conjugates.

Compton BJ, Tang CW, Johnston KA, Osmond TL, Hayman CM, Larsen DS, Hermans IF, Painter GF.

Org Lett. 2015 Dec 18;17(24):5954-7. doi: 10.1021/acs.orglett.5b02836. Epub 2015 Nov 25.

PMID:
26606283
13.

Expression of CD1a and Type-1 Polarization Are Dissociated in Human Monocyte-Derived Dendritic Cells.

Mester B, Bauer E, Wood CE, Hermans IF, Gasser O.

PLoS One. 2015 Oct 13;10(10):e0140432. doi: 10.1371/journal.pone.0140432. eCollection 2015.

14.

Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell Therapy.

Gibbins JD, Ancelet LR, Osmond TL, Petersen TR, Hermans IF.

J Immunother. 2015 Oct;38(8):321-9. doi: 10.1097/CJI.0000000000000096.

PMID:
26325376
15.

NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.

Anderson RJ, Compton BJ, Tang CW, Authier-Hall A, Hayman CM, Swinerd GW, Kowalczyk R, Harris P, Brimble MA, Larsen DS, Gasser O, Weinkove R, Hermans IF, Painter GF.

Chem Sci. 2015 Sep 1;6(9):5120-5127. doi: 10.1039/c4sc03599b. Epub 2015 Jun 25.

16.

An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.

Weinkove R, Ancelet LR, Gibbins JD, Hermans IF.

Oncoimmunology. 2015 Jan 22;4(4):e995568. eCollection 2015 Apr.

17.

Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming.

Osmond TL, Farrand KJ, Painter GF, Ruedl C, Petersen TR, Hermans IF.

J Immunol. 2015 Aug 1;195(3):821-31. doi: 10.4049/jimmunol.1401751. Epub 2015 Jun 15.

18.

Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, Ancelet LR, Mester B, Sharples KJ, Findlay MP, Hamilton DA, Hermans IF.

J Neurooncol. 2015 Jan;121(2):319-29. doi: 10.1007/s11060-014-1635-7. Epub 2014 Oct 31.

PMID:
25366363
19.

Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.

Authier A, Farrand KJ, Broadley KW, Ancelet LR, Hunn MK, Stone S, McConnell MJ, Hermans IF.

Int J Cancer. 2015 Jun 1;136(11):2566-78. doi: 10.1002/ijc.29309. Epub 2014 Nov 12.

20.

A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.

Anderson RJ, Tang CW, Daniels NJ, Compton BJ, Hayman CM, Johnston KA, Knight DA, Gasser O, Poyntz HC, Ferguson PM, Larsen DS, Ronchese F, Painter GF, Hermans IF.

Nat Chem Biol. 2014 Nov;10(11):943-9. doi: 10.1038/nchembio.1640. Epub 2014 Oct 5.

PMID:
25282504
21.

An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment.

Gibbins JD, Ancelet LR, Weinkove R, Compton BJ, Painter GF, Petersen TR, Hermans IF.

Blood. 2014 Nov 6;124(19):2953-63. doi: 10.1182/blood-2014-04-568956. Epub 2014 Sep 18.

22.

Batf3-independent langerin- CX3CR1- CD8α+ splenic DCs represent a precursor for classical cross-presenting CD8α+ DCs.

Petersen TR, Knight DA, Tang CW, Osmond TL, Hermans IF.

J Leukoc Biol. 2014 Dec;96(6):1001-10. doi: 10.1189/jlb.1A0314-130R. Epub 2014 Aug 28.

PMID:
25170118
23.

Sustained in vivo depletion of splenic langerin(+) CD8α(+) dendritic cells is well-tolerated by lang-DTREGFP mice.

Prendergast KA, Osmond TL, Ochiai S, Hermans IF, Kirman JR.

J Immunol Methods. 2014 Apr;406:104-9. doi: 10.1016/j.jim.2014.02.005. Epub 2014 Feb 18.

PMID:
24556588
24.

Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletion.

Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F.

J Immunol Methods. 2013 Oct 31;396(1-2):152-6. doi: 10.1016/j.jim.2013.07.004. Epub 2013 Jul 31.

PMID:
23911312
25.

The control of CD8+ T cell responses is preserved in perforin-deficient mice and released by depletion of CD4+CD25+ regulatory T cells.

Ataera H, Simkins HM, Hyde E, Yang J, Hermans IF, Petersen TR, Ronchese F.

J Leukoc Biol. 2013 Oct;94(4):825-33. doi: 10.1189/jlb.0413200. Epub 2013 Jul 24.

PMID:
23883515
26.

Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.

Hunn MK, Hermans IF.

Oncoimmunology. 2013 Apr 1;2(4):e23789.

27.

Using magnetic resonance imaging to evaluate dendritic cell-based vaccination.

Ferguson PM, Slocombe A, Tilley RD, Hermans IF.

PLoS One. 2013 May 29;8(5):e65318. doi: 10.1371/journal.pone.0065318. Print 2013.

28.

Strongly magnetic iron nanoparticles improve the diagnosis of small tumours in the reticuloendothelial system by magnetic resonance imaging.

Ferguson PM, Feindel KW, Slocombe A, MacKay M, Wignall T, Delahunt B, Tilley RD, Hermans IF.

PLoS One. 2013;8(2):e56572. doi: 10.1371/journal.pone.0056572. Epub 2013 Feb 20.

29.

Identifying leukocyte populations in fresh and cryopreserved sputum using flow cytometry.

Brooks CR, van Dalen CJ, Hermans IF, Douwes J.

Cytometry B Clin Cytom. 2013 Mar;84(2):104-13. doi: 10.1002/cyto.b.21069. Epub 2013 Jan 22.

30.

Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.

Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, Field CS, Petersen T, McConnell MJ, Hermans IF.

Clin Cancer Res. 2012 Dec 1;18(23):6446-59. doi: 10.1158/1078-0432.CCR-12-0704. Epub 2012 Nov 12.

31.

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F.

Haematologica. 2013 Mar;98(3):376-84. doi: 10.3324/haematol.2012.072835. Epub 2012 Oct 12.

32.

Immature murine NKT cells pass through a stage of developmentally programmed innate IL-4 secretion.

Dickgreber N, Farrand KJ, van Panhuys N, Knight DA, McKee SJ, Chong ML, Miranda-Hernandez S, Baxter AG, Locksley RM, Le Gros G, Hermans IF.

J Leukoc Biol. 2012 Nov;92(5):999-1009. doi: 10.1189/jlb.0512242. Epub 2012 Aug 31.

33.

Species-specific activity of glycolipid ligands for invariant NKT cells.

Dangerfield EM, Cheng JM, Knight DA, Weinkove R, Dunbar PR, Hermans IF, Timmer MS, Stocker BL.

Chembiochem. 2012 Jun 18;13(9):1349-56. doi: 10.1002/cbic.201200095. Epub 2012 May 25.

PMID:
22639457
34.

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.

McKee SJ, Young VL, Clow F, Hayman CM, Baird MA, Hermans IF, Young SL, Ward VK.

J Control Release. 2012 May 10;159(3):338-45. doi: 10.1016/j.jconrel.2012.02.015. Epub 2012 Feb 22.

PMID:
22386518
35.

Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging.

Herman DA, Ferguson P, Cheong S, Hermans IF, Ruck BJ, Allan KM, Prabakar S, Spencer JL, Lendrum CD, Tilley RD.

Chem Commun (Camb). 2011 Aug 28;47(32):9221-3. doi: 10.1039/c1cc13416g. Epub 2011 Jul 15.

PMID:
21761066
36.

Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.

Petersen TR, Sika-Paotonu D, Knight DA, Simkins HM, Hermans IF.

PLoS One. 2011 Mar 31;6(3):e17657. doi: 10.1371/journal.pone.0017657.

37.

Simple synthesis and functionalization of iron nanoparticles for magnetic resonance imaging.

Cheong S, Ferguson P, Feindel KW, Hermans IF, Callaghan PT, Meyer C, Slocombe A, Su CH, Cheng FY, Yeh CS, Ingham B, Toney MF, Tilley RD.

Angew Chem Int Ed Engl. 2011 Apr 26;50(18):4206-9. doi: 10.1002/anie.201100562. Epub 2011 Apr 6. No abstract available.

PMID:
21472950
38.

An improved synthesis of dansylated α-galactosylceramide and its use as a fluorescent probe for the monitoring of glycolipid uptake by cells.

Cheng JM, Chee SH, Knight DA, Acha-Orbea H, Hermans IF, Timmer MS, Stocker BL.

Carbohydr Res. 2011 May 15;346(7):914-26. doi: 10.1016/j.carres.2011.02.014. Epub 2011 Feb 19.

PMID:
21463856
39.

Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.

Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ.

Stem Cells. 2011 Mar;29(3):452-61. doi: 10.1002/stem.582.

40.

Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.

Simkins HM, Hyde E, Farrand KJ, Ong ML, Degli-Esposti MA, Hermans IF, Ronchese F.

J Leukoc Biol. 2011 May;89(5):753-62. doi: 10.1189/jlb.0910480. Epub 2011 Feb 4.

PMID:
21297009
41.

MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.

Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA.

Vaccine. 2011 Jan 10;29(3):545-57. doi: 10.1016/j.vaccine.2010.10.040. Epub 2010 Oct 27.

PMID:
21034827
42.

Invariant natural killer T cells and asthma: immunologic reality or methodologic artifact?

Brooks CR, Weinkove R, Hermans IF, van Dalen CJ, Douwes J.

J Allergy Clin Immunol. 2010 Oct;126(4):882-5. doi: 10.1016/j.jaci.2010.06.041. Epub 2010 Aug 16. No abstract available.

PMID:
20719374
43.

Tumor antigen presentation by dendritic cells.

Petersen TR, Dickgreber N, Hermans IF.

Crit Rev Immunol. 2010;30(4):345-86. Review.

PMID:
20666707
44.

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.

Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F, Hermans IF.

Immunol Cell Biol. 2010 Jul;88(5):596-604. doi: 10.1038/icb.2010.9. Epub 2010 Feb 9.

PMID:
20142835
45.

Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.

Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF.

J Immunol. 2009 Dec 15;183(12):7732-42. doi: 10.4049/jimmunol.0902707.

46.

Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.

Tripp CH, Sparber F, Hermans IF, Romani N, Stoitzner P.

J Immunol. 2009 Jun 15;182(12):7644-54. doi: 10.4049/jimmunol.0900134.

47.

Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy.

Dickgreber N, Stoitzner P, Bai Y, Price KM, Farrand KJ, Manning K, Angel CE, Dunbar PR, Ronchese F, Fraser JD, Bäckström BT, Hermans IF.

J Immunol. 2009 Feb 1;182(3):1260-9.

48.

Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo.

Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF, Ritchie DS, Yang J, Ronchese F.

J Immunol. 2008 Dec 15;181(12):8356-62.

49.

Tumor immunotherapy by epicutaneous immunization requires langerhans cells.

Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F.

J Immunol. 2008 Feb 1;180(3):1991-8.

50.

Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.

Matthews KE, Qin JS, Yang J, Hermans IF, Palmowski MJ, Cerundolo V, Ronchese F.

J Immunol. 2007 Nov 1;179(9):5738-47.

Supplemental Content

Loading ...
Support Center